UroGen Pharma Ltd Stock Analysis
Technical stock analysis for 18 January 2019
UroGen Pharma Ltd fell by -1.75% in the last day from $52.03 to $51.12 The price has risen in 6 of the last 10 days , but is still down by -0.66% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -90 995 shares and in total 67 643 shares bought and sold for approximately $3.46 million.
Close price at the end of the last trading day (Friday, 18th Jan 2019) of the URGN stock was $51.12. This is 1.75% less than the trading day before Thursday, 17th Jan 2019.
During day the stock fluctuated 2.90% from a day low at $51.02 to a day high of $52.50.
30 day high of the URGN stock price was $55.49 and low was $40.61.
90 day high was $55.49 and low was $36.95.
52 week high for the UroGen Pharma Ltd - $69.57 and low - $36.95.
UroGen Pharma Ltd lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 16.53% during the next 3 months and, with 90% probability hold a price between $51.96 and $64.93 at the end of this period.
UroGen Pharma Ltd holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at $50.84 and $47.36. A break down below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Thursday January 17, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Relative Strength Index (RSI)
RSI14 is 66 and the stock is currently not being overbought or oversold
Support & Resistance
On the downside, the stock finds support just below today's level from accumulated volume at $47.57 and $47.00.
There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, UroGen Pharma Ltd finds support just below today's level at $47.57. If this is broken, then the next support from accumulated volume will be at $47.00 and $42.52.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.48 between high and low, or 2.90%. For the last week, the stock has had a daily average volatility of 3.90%.
Our recommended stoploss: $48.41 (-5.30%) (This stock has high daily movements and this gives high risk. There is a sell signal from pivot top found 1 days ago.)
Very Low Low Medium High Very High
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Strong Buy Candidate to a Buy Candidate.
|URGN $51.12 $-0.91(-1.75%)|
URGN is down $0.91 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month system that more than doubles the S&P 500.
Click here – the URGN analysis is free »